PT3539961T - Derivados de amida policíclica como inibidores de cdk9 - Google Patents

Derivados de amida policíclica como inibidores de cdk9

Info

Publication number
PT3539961T
PT3539961T PT191657261T PT19165726T PT3539961T PT 3539961 T PT3539961 T PT 3539961T PT 191657261 T PT191657261 T PT 191657261T PT 19165726 T PT19165726 T PT 19165726T PT 3539961 T PT3539961 T PT 3539961T
Authority
PT
Portugal
Prior art keywords
amide derivatives
cdk9 inhibitors
polycyclic amide
polycyclic
cdk9
Prior art date
Application number
PT191657261T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PT3539961T publication Critical patent/PT3539961T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Detergent Compositions (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT191657261T 2015-06-29 2016-06-27 Derivados de amida policíclica como inibidores de cdk9 PT3539961T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562185852P 2015-06-29 2015-06-29

Publications (1)

Publication Number Publication Date
PT3539961T true PT3539961T (pt) 2021-12-20

Family

ID=56292699

Family Applications (2)

Application Number Title Priority Date Filing Date
PT191657261T PT3539961T (pt) 2015-06-29 2016-06-27 Derivados de amida policíclica como inibidores de cdk9
PT16733459T PT3313838T (pt) 2015-06-29 2016-06-27 Derivados de amida policíclica como inibidores de cdk9

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT16733459T PT3313838T (pt) 2015-06-29 2016-06-27 Derivados de amida policíclica como inibidores de cdk9

Country Status (38)

Country Link
US (4) US9845331B2 (https=)
EP (2) EP3539961B1 (https=)
JP (1) JP6997627B2 (https=)
KR (1) KR102663113B1 (https=)
CN (1) CN107873028B (https=)
AR (1) AR105179A1 (https=)
AU (1) AU2016286200B2 (https=)
BR (1) BR122019013677B1 (https=)
CA (1) CA2989499C (https=)
CL (1) CL2017003306A1 (https=)
CO (1) CO2017013713A2 (https=)
CR (2) CR20210297A (https=)
CY (2) CY1122111T1 (https=)
DK (2) DK3313838T3 (https=)
DO (2) DOP2017000295A (https=)
EA (1) EA035383B1 (https=)
ES (2) ES2728356T3 (https=)
HR (2) HRP20190748T1 (https=)
HU (2) HUE043440T2 (https=)
IL (1) IL256393B (https=)
LT (2) LT3313838T (https=)
ME (1) ME03404B (https=)
MX (1) MX371034B (https=)
MY (1) MY201673A (https=)
NI (1) NI201700174A (https=)
PE (1) PE20180530A1 (https=)
PH (1) PH12017502334B1 (https=)
PL (2) PL3313838T3 (https=)
PT (2) PT3539961T (https=)
RS (2) RS58712B1 (https=)
SI (2) SI3313838T1 (https=)
SM (2) SMT202200005T1 (https=)
SV (1) SV2017005598A (https=)
TN (1) TN2017000486A1 (https=)
TR (1) TR201909286T4 (https=)
TW (1) TWI723028B (https=)
WO (1) WO2017001354A1 (https=)
ZA (1) ZA201800563B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020005039A2 (pt) 2017-09-25 2020-09-15 Astrazeneca Ab combinação de um inibidor de btk e um inibidor de cdk9 para tratar câncer
EP3694506B1 (en) * 2017-10-09 2023-08-02 Merck Sharp & Dohme LLC Novel substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
CN108129288B (zh) * 2017-12-27 2021-01-22 上海毕得医药科技股份有限公司 一种反式-3-羟基环丁基甲酸的合成方法
TWI810397B (zh) 2018-11-14 2023-08-01 瑞典商阿斯特捷利康公司 治療癌症之方法
WO2020259556A1 (zh) * 2019-06-27 2020-12-30 南京明德新药研发有限公司 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物
US20220324830A1 (en) 2019-09-11 2022-10-13 Prelude Therapeutics, Incorporated CDK Inhibitors And Their Use As Pharmaceuticals
AU2020401999B2 (en) * 2019-12-09 2024-01-18 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Compound as cyclin-dependent kinase 9 inhibitor and use thereof
WO2021227906A1 (zh) * 2020-05-12 2021-11-18 苏州阿尔脉生物科技有限公司 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途
JP7406008B2 (ja) * 2020-05-12 2023-12-26 蘇州阿尓脈生物科技有限公司 Cdk9阻害剤としての多環式アミド系誘導体、その調製方法及び用途
EP4171654A1 (en) * 2020-06-24 2023-05-03 AstraZeneca UK Limited Combination of antibody-drug conjugate and cdk9 inhibitor
EP4194450A4 (en) 2020-08-07 2024-10-30 Pharmablock Sciences (Nanjing), Inc. CDK9 INHIBITOR AND USE THEREOF
TWI809330B (zh) * 2020-11-20 2023-07-21 大陸商勁方醫藥科技(上海)有限公司 Cdk9抑制劑的多晶型物及其製法和用途
CN115381824B (zh) * 2021-05-24 2024-11-05 石药集团中奇制药技术(石家庄)有限公司 周期蛋白依赖性激酶9抑制剂的用途
CN115381823B (zh) * 2021-05-24 2024-11-05 石药集团中奇制药技术(石家庄)有限公司 一种周期蛋白依赖性激酶9抑制剂的用途
CN117813289A (zh) * 2021-07-14 2024-04-02 上海海雁医药科技有限公司 吡唑衍生物及其中间体和制备方法
CN115703738B (zh) * 2021-08-16 2024-06-21 中国科学院上海药物研究所 含2-芳杂环取代的脲类化合物、其制备方法和用途
US20230279016A1 (en) * 2021-12-23 2023-09-07 The Katholieke Universiteit Leuven Tetrahydropyrazolopyrimidines and Related Analogs for Inhibiting YAP/TAZ-TEAD
JP2025528223A (ja) 2022-08-17 2025-08-26 コリア リサーチ インスティテュート オブ ケミカル テクノロジー Cdk2及び/又はcdk9の抑制又は分解用化合物及びこれらの医薬用途
CN117659022A (zh) * 2022-09-06 2024-03-08 苏州阿尔脉生物科技有限公司 脲基取代吡啶类化合物、包含其的药物组合物及其医药用途
US20240360075A1 (en) * 2023-04-19 2024-10-31 Alcon Inc. N-substituted c6 cyclyl carboxamide compounds and uses thereof
WO2025076115A1 (en) * 2023-10-02 2025-04-10 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals
WO2026024933A1 (en) * 2024-07-24 2026-01-29 Prelude Therapeutics Incorporated Cdk inhibitors and their use as pharmaceuticals

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133192A1 (ja) * 2007-04-19 2008-11-06 Takeda Pharmaceutical Company Limited 縮合イミダゾール化合物およびその用途
US8389521B2 (en) 2007-04-24 2013-03-05 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
WO2008129071A1 (en) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
WO2008129070A1 (en) 2007-04-24 2008-10-30 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
JP5566880B2 (ja) 2007-04-24 2014-08-06 インゲニウム ファーマシューティカルズ ジーエムビーエイチ プロテインキナーゼの阻害剤としての4,6−二置換アミノピリミジン誘導体
WO2008132138A1 (en) * 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
AU2008309517B2 (en) 2007-10-12 2013-03-14 Astrazeneca Ab Inhibitors of protein kinases
CA2771568A1 (en) * 2009-09-04 2011-03-10 Novartis Ag Heteroaryl compounds as kinase inhibitors
US20110113038A1 (en) 2009-11-12 2011-05-12 International Business Machines Corporation Search term security
GB201002911D0 (en) * 2010-02-19 2010-04-07 Medical Res Council Compound
CA2789189A1 (en) 2010-03-10 2011-09-15 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
AR081810A1 (es) * 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
WO2012101064A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
JP2014506878A (ja) * 2011-01-28 2014-03-20 ノバルティス アーゲー Cdk9阻害剤としての置換ビ−ヘテロアリール化合物およびそれらの使用
WO2012101063A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyridine biaryl compounds and their uses
RU2627272C2 (ru) * 2011-10-06 2017-08-04 Байер Интеллектчуал Проперти Гмбх Гетероциклилпиридинилпиразолы
TW201444820A (zh) 2013-03-13 2014-12-01 Abbvie Inc 吡啶cdk9激酶抑制劑
WO2014159999A1 (en) 2013-03-13 2014-10-02 Abbvie Inc. Cdk9 kinase inhibitors
US9073922B2 (en) * 2013-03-14 2015-07-07 Abbvie, Inc. Pyrrolo[2,3-B]pyridine CDK9 kinase inhibitors
CA2903538A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Pyrrolopyrimindine cdk9 kinase inhibitors

Also Published As

Publication number Publication date
EP3313838A1 (en) 2018-05-02
IL256393B (en) 2021-12-01
SI3313838T1 (sl) 2019-06-28
CN107873028A (zh) 2018-04-03
AU2016286200A1 (en) 2018-02-08
US20180093998A1 (en) 2018-04-05
HUE043440T2 (hu) 2019-08-28
PE20180530A1 (es) 2018-03-19
EA201890094A1 (ru) 2018-07-31
EP3539961B1 (en) 2021-10-06
PT3313838T (pt) 2019-06-24
TR201909286T4 (tr) 2019-07-22
JP2018522869A (ja) 2018-08-16
PL3539961T3 (pl) 2022-02-14
AU2016286200B2 (en) 2018-10-04
NI201700174A (es) 2018-10-19
US9845331B2 (en) 2017-12-19
LT3313838T (lt) 2019-06-10
CR20170596A (es) 2018-07-04
US20220340592A1 (en) 2022-10-27
PH12017502334A1 (en) 2018-06-25
EA035383B1 (ru) 2020-06-04
AR105179A1 (es) 2017-09-13
SV2017005598A (es) 2018-02-23
IL256393A (en) 2018-02-28
RS58712B1 (sr) 2019-06-28
WO2017001354A1 (en) 2017-01-05
CO2017013713A2 (es) 2018-03-28
EP3539961A1 (en) 2019-09-18
ES2728356T3 (es) 2019-10-23
US20210171541A1 (en) 2021-06-10
CY1125066T1 (el) 2023-03-24
TW201718573A (zh) 2017-06-01
TN2017000486A1 (en) 2019-04-12
KR20180021830A (ko) 2018-03-05
HRP20190748T1 (hr) 2019-06-14
EP3313838B1 (en) 2019-04-03
SMT201900298T1 (it) 2019-07-11
MY201673A (en) 2024-03-12
LT3539961T (lt) 2021-12-27
BR122019013677B1 (pt) 2024-01-02
SI3539961T1 (sl) 2022-02-28
US10717746B2 (en) 2020-07-21
PH12017502334B1 (en) 2023-05-26
RS62781B1 (sr) 2022-01-31
CL2017003306A1 (es) 2018-06-29
CA2989499A1 (en) 2017-01-05
PL3313838T3 (pl) 2019-08-30
DK3313838T3 (da) 2019-06-11
DOP2018000207A (es) 2018-10-15
HUE057343T2 (hu) 2022-05-28
BR112017027394A2 (pt) 2018-11-06
DOP2017000295A (es) 2017-12-31
SMT202200005T1 (it) 2022-03-21
ME03404B (me) 2020-01-20
DK3539961T3 (da) 2022-01-03
ZA201800563B (en) 2022-08-31
US20160376287A1 (en) 2016-12-29
CA2989499C (en) 2023-10-31
CN107873028B (zh) 2021-02-02
KR102663113B1 (ko) 2024-05-02
CR20210297A (es) 2021-09-29
TWI723028B (zh) 2021-04-01
US11352369B2 (en) 2022-06-07
MX2017016244A (es) 2018-04-20
CY1122111T1 (el) 2020-11-25
HRP20211970T1 (hr) 2022-03-18
JP6997627B2 (ja) 2022-01-17
MX371034B (es) 2020-01-13
ES2902148T3 (es) 2022-03-25

Similar Documents

Publication Publication Date Title
PT3539961T (pt) Derivados de amida policíclica como inibidores de cdk9
PT3580220T (pt) Aminotriazolopiridinas como inibidores de quinase
PT3209656T (pt) Compostos de indol carboxamida úteis como inibidores de quinase
DK3319956T3 (da) Substituerede oxopyridinderivater
EP3247692A4 (en) INHIBITORS OF TRKA KINASE
PT3105226T (pt) Ciclopropilaminas como inibidores de lsd1
HRP20181650T1 (hr) Biciklički heterociklički derivati kao inhibitori bromodomene
GEAP201814347A (en) Substituted dihydroisoquinoline compounds
PT3288944T (pt) Imidazopirazinonas como inibidores de pde1
EP3394068A4 (en) TDO2 INHIBITORS
PT3457851T (pt) Derivados de sobetiroma
EP3303283A4 (en) Fto inhibitors
HRP20190127T1 (hr) Derivati pirolidinona kao inhibitori metap-2
DK3371168T3 (da) Indolin-2-on-derivater
EP3309163A4 (en) SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE
FR3023290B1 (fr) Derives de flavaglines
PT3131898T (pt) Derivados de fluoroalquilfluoreno
HRP20190336T1 (hr) Derivati 6-alkinilpiridina kao smac-mimetici
BR112017011306A2 (pt) derivados heterocíclicos de amida com substituintes contendo enxofre ativos em termos pesticidas
DK3371163T3 (da) Pyrrolidinderivater
EP3868751C0 (en) 2-AMINOQUINAZOLINE DERIVATIVES AS P70S6 KINASE INHIBITORS
CL2016001959A1 (es) Hexahidrofuropirroles como inhibidores de pde1
HUE046994T2 (hu) Pirido-oxazinon származékok TNAP inhibitorokként
BR112016026725A2 (pt) Derivados de aminoéster
PT3303316T (pt) Derivados de etinilo